Skip directly to content

Minimize RSR Award Detail

Research Spending & Results

Award Detail

Doing Business As Name:THERANEUTRICS LLC
  • Christoph Geisler
  • (307) 340-1616
Award Date:07/06/2020
Estimated Total Award Amount: $ 224,840
Funds Obligated to Date: $ 224,840
  • FY 2020=$224,840
Start Date:07/01/2020
End Date:06/30/2021
Transaction Type:Grant
Awarding Agency Code:4900
Funding Agency Code:4900
CFDA Number:47.041
Primary Program Source:040100 NSF RESEARCH & RELATED ACTIVIT
Award Title or Description:SBIR Phase I: Engineering probiotic yeast to treat hyperuricemia and gout
Federal Award ID Number:2014679
DUNS ID:102456553
Program:SBIR Phase I
Program Officer:
  • Alastair Monk
  • (703) 292-4392

Awardee Location

Street:1938 HARNEY ST STE 247
Awardee Cong. District:00

Primary Place of Performance

Street:1938 Harney Street STE 247
Cong. District:00

Abstract at Time of Award

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project will be the development of an engineered probiotic as an treatment for hyperuricemia and gout. Acute gout episodes cause debilitating pain and hypersensitivity, seriously impairing mobility. Over time, joint damage and deformity, chronic usage-related pain, and disfigurement follow. Although gout can be treated by drugs that lower uric acid levels, these drugs have significant drawbacks for many patients: they have limited effectiveness, are associated with serious side effects, and may be expensive. Gout patients experience an estimated increase of 5 absence days annually with an incremental cost of $3,000 per patient. The 9.2 million gout patients in the USA spend more than $1.3 billion per year on gout drugs. Moreover, roughly half take additional supplements. The proposed project will develop a novel probiotic strain to address hyperuricemia. This Small Business Innovation Research (SBIR) Phase I project will advance hyperuricemia treatment using an engineered probiotic. The proposed treatment is based on the observation that enzymatically degrading uric acid in the intestine reduces serum uric acid levels, unlike conventional treatments targeting the circulatory system, the urinary tract, or function systemically. This project will use genetic screening to identify a probiotic strain to break down uric acid, engineering it to prevent gene mobility across species and avoid transfer of antibiotic resistance to the intestinal microbiome. Finally, we will confirm safety and efficacy in a mouse model of hyperuricemia. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

For specific questions or comments about this information including the NSF Project Outcomes Report, contact us.